Amarillo Biosciences (OTCMKTS:AMAR) versus Spruce Biosciences (NASDAQ:SPRB) Head to Head Survey

Spruce Biosciences (NASDAQ:SPRB) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Volatility and Risk

Spruce Biosciences has a beta of 3.62, suggesting that its share price is 262% more volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.

Profitability

This table compares Spruce Biosciences and Amarillo Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
Amarillo Biosciences	-41,453.98%	N/A	-574.29%

Analyst Recommendations

This is a summary of current ratings and target prices for Spruce Biosciences and Amarillo Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	3	4	0	2.38
Amarillo Biosciences	0	0	0	0	0.00

Spruce Biosciences presently has a consensus target price of $170.10, suggesting a potential upside of 151.50%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Amarillo Biosciences.

Earnings and Valuation

This table compares Spruce Biosciences and Amarillo Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	18.87	-$38.97 million	($51.72)	-1.31
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A

Amarillo Biosciences has lower revenue, but higher earnings than Spruce Biosciences.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 34.4% of Amarillo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Spruce Biosciences beats Amarillo Biosciences on 8 of the 11 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.